

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED
Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.
STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th June, 2021

Rupees in Lakhs

Sl.No	Particulars	Quarter Ended			Year Ended 31-03-2021 Audited
		30-06-2021 Un Audited	31-03-2021 Audited	30-06-2020 Un Audited	
1	Income				
	(a) Revenue from Operations	1376.04	1355.89	344.60	4139.36
	(b) Other Income	7.94	7.85	31.46	92.43
	(c) Unbilled Revenue	0	0.00	-33.80	53.00
	Total income	1,383.98	1,363.74	342.26	4,284.79
2	Expenses				
	(a) Cost of Material Consumed	83.69	117.14	10.78	274.55
	(b) Purchase of stock-in-trade				-
	(c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-14.79	(33.70)	2.40	(210.30)
	(d) Employee benefit expense	331.94	275.42	166.98	917.72
	(e) Finance Cost	26.74	33.13	44.97	171.86
	(f) Depreciation and Amortisation expense	99.23	98.31	98.51	395.52
	(g) Other Expenses	431.91	526.98	141.39	1417.59
	Total Expenses	958.72	1,017.28	465.03	2,966.94
3	Profit before exceptional items and Tax	425.26	346.46	-122.77	1,317.85
4	Add(+)/Less(-) Exceptional Items	-	-	-	-
5	Profit/ (Loss) before Tax	425.26	346.46	-122.77	1,317.85
6	Tax Expenses	138.19	-0.24	28.31	191.92
7	Profit(Loss) for the Period from Continuing Operations	287.07	346.70	-94.46	1,125.93
8	Profit(Loss) from Discontinuing Operations	-	-	-	-
9	Tax Expenses on discontinuing Operations	-	-	-	-

Sl.No	Particulars	Quarter Ended			Year Ended
		30-06-2021 Un Audited	31-03-2021 Audited	30-06-2020 Un Audited	
10	Profit(Loss) from Discontinuing Operations after Tax			-	-
11	Profit(Loss) for the period	287.07	346.70	-94.46	1,125.93
12	Other Comprehensive Income				
	A (i) Items that will not be reclassified to profit or loss	0.63	6.80	0.51	5.96
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
13	Total Comprehensive Income for the period	287.70	353.50	-93.95	1,131.89
14	Paid Up Equity Share Capital (Face Value of Rs.10/- each)	1,530.15	1,530.15	1,530.15	1,530.15
15	Other equity excluding revaluation reserve		-	-	2094.74
16	Earnings per Equity share (for continuing operations)				
	a) Basic (Amount in Rupees)	1.88	2.31	-0.61	7.40
	b) Diluted (Amount in Rupees)	1.88	2.31	-0.61	7.40
17	Earnings per Equity share (for discontinued operations)				
	a) Basic (Amount in Rupees)		-	-	-
	b) Diluted (Amount in Rupees)		-	-	-
18	Earnings per Equity share (for Continuing & discontinued operations)				
	a) Basic (Amount in Rupees)	1.88	2.31	-0.61	7.40
	b) Diluted (Amount in Rupees)	1.88	2.31	-0.61	7.40

Notes to the Standalone Audited Financial Results

- The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015
- The above results have been reviewed by the Audit Committee at its meeting held on 09.08.2021 and approved by the Board of Directors of the Company on the same date. These Results are also subjected to Limited Review by the Company's Statutory Auditors.
- During the year, Company is operating in only one segment i.e., Clinical Research Services
- The company has considered the possible effects that may result from the pandemic relating to Covid 19 on the carrying amounts of receivables, inventories, property, plant and equipment and intangible assets. In developing the assumptions relating to the future possible uncertainties in the global economic conditions, the Company has, at the date of approval of these standalone financial results, used internal and external sources of information, including economic forecasts and estimates from market sources, on the expected future performance of the company. On the basis of evaluation and current indicators of future economic conditions, the Company expects to recover the carrying amounts of the above assets and does not anticipate any impairment to these financial and non-financial assets. However, the impact assessment of Covid-19 is a continuing process, given the uncertainties associated with its nature and duration. The company will continue to monitor any material changes in future economic figures for the previous periods have been rearranged wherever necessary.

for Jeevan Scientific Technology Limited

On behalf of the Board of Directors

K. Krishna Kishore

Vice Chairman & Managing Director

M Srikanth Sasidhar

CFO

Place:Hyderabad
Date:09.08.2021

